Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Therapeutic potential of targeting IL-17 and IL-23 in sepsis.

Bosmann M, Ward PA.

Clin Transl Med. 2012 Apr 27;1(1):4. doi: 10.1186/2001-1326-1-4.

2.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
3.

Applied molecular biology of sepsis.

Remick DG.

J Crit Care. 1995 Dec;10(4):198-212. Review.

PMID:
8924969
4.

Interleukin-18: a novel prognostic cytokine in bacteria-induced sepsis.

Tschoeke SK, Oberholzer A, Moldawer LL.

Crit Care Med. 2006 Apr;34(4):1225-33. Review.

PMID:
16540967
5.

Use of animal model of sepsis to evaluate novel herbal therapies.

Li W, Zhu S, Zhang Y, Li J, Sama AE, Wang P, Wang H.

J Vis Exp. 2012 Apr 11;(62). pii: 3926. doi: 10.3791/3926.

6.

Antithrombotic Agents in the Management of Sepsis.

Iqbal O, Tobu M, Hoppenstead D, Aziz S, Messmore H, Fareed J.

Turk J Haematol. 2002 Sep 5;19(3):349-89.

PMID:
27264974
7.

Experimental therapeutic strategies for severe sepsis: mediators and mechanisms.

Parrish WR, Gallowitsch-Puerta M, Czura CJ, Tracey KJ.

Ann N Y Acad Sci. 2008 Nov;1144:210-36. doi: 10.1196/annals.1418.011. Review.

PMID:
19076379
8.

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.

Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA; IL-1RA Sepsis Syndrome Study Group.

Crit Care Med. 1994 Jan;22(1):12-21.

PMID:
8124953
9.

[The cost of sepsis].

Moerer O, Burchardi H.

Anaesthesist. 2006 Jun;55 Suppl 1:36-42. Review. German.

PMID:
16685555
10.

Cytokines and Escherichia coli Sepsis.

Kaech C, Bochud PY, Calandra T.

EcoSal Plus. 2006 Jan;2(1). doi: 10.1128/ecosalplus.8.8.15.

PMID:
26443575
11.

Citrulline: a potential immunomodulator in sepsis.

Asgeirsson T, Zhang S, Nunoo R, Mascarenas C, Dujovny N, Luchtefeld M, Cavey GS, Senagore A.

Surgery. 2011 Oct;150(4):744-51. doi: 10.1016/j.surg.2011.08.024.

PMID:
22000187
12.

Nanotechnology: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(19):1-43. Epub 2006 Nov 1.

13.

Antithrombin replacement in patients with sepsis and septic shock.

Giudici D, Baudo F, Palareti G, Ravizza A, Ridolfi L, D' Angelo A.

Haematologica. 1999 May;84(5):452-60. Review.

14.

The growing spectrum of anti-inflammatory interleukins and their potential roles in the development of sepsis.

Zhao HQ, Li WM, Lu ZQ, Sheng ZY, Yao YM.

J Interferon Cytokine Res. 2015 Apr;35(4):242-51. doi: 10.1089/jir.2014.0119. Epub 2014 Dec 17. Review.

PMID:
25517926
15.

Targeting high mobility group box 1 as a late-acting mediator of inflammation.

Czura CJ, Tracey KJ.

Crit Care Med. 2003 Jan;31(1 Suppl):S46-50. Review.

PMID:
12544976
16.

Antithrombotic agents in the treatment of severe sepsis.

Iqbal O, Messmore H, Fareed J, Ahmad S, Hoppensteadt D, Hazar S, Tobu M, Aziz S, Wehrmacher W.

Expert Opin Emerg Drugs. 2002 May;7(1):111-39.

PMID:
15989540
17.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
18.

Advances in the understanding of clinical manifestations and therapy of severe sepsis: an update for critical care nurses.

Ely EW, Kleinpell RM, Goyette RE.

Am J Crit Care. 2003 Mar;12(2):120-33; quiz 134-5. Review.

19.

Sepsis as a model of SIRS.

Bhatia M, He M, Zhang H, Moochhala S.

Front Biosci (Landmark Ed). 2009 Jan 1;14:4703-11. Review.

PMID:
19273383
20.

[New therapeutic strategies in severe sepsis and septic shock].

Oddo M, Schaller MD, Calandra T, Liaudet L.

Rev Med Suisse Romande. 2004 Jun;124(6):329-32. Review. French.

PMID:
15293439

Supplemental Content

Support Center